Literature DB >> 21804136

Peritoneal morphology after long-term peritoneal dialysis with biocompatible fluid: recent clinical practice in Japan.

Nobuhiro Ayuzawa1, Yoshitaka Ishibashi, Yutaka Takazawa, Haruki Kume, Toshiro Fujita.   

Abstract

BACKGROUND: Morphology changes of the peritoneal membrane after long-term peritoneal dialysis (PD) consist of denudation of peritoneal mesothelial cells, interstitial sclerosis, and hyalinizing vasculopathy. Those changes are considered to be the result of uremia and bioincompatible effects of conventional acidic lactate-buffered dialysate with glucose degradation products (GDPs). In the last decade, biocompatible dialysate with neutral pH and low GDPs has become widely used. Clinical practice has been modified in Japan, especially for anuric patients, and now includes the use of hybrid therapy. The impact on peritoneal morphology has not been well reported.
OBJECTIVE: The aim of the present study was to investigate the long-term effect on peritoneal morphology and function of biocompatible fluid use and current clinical practice in Japan, including hybrid dialysis therapy.
METHODS: We evaluated peritoneal biopsy specimens from patients who had undergone PD for more than 3 years. We used the average peritoneal thickness (APT) of the submesothelial compact zone as a marker of interstitial sclerosis and the lumen/vessel diameter ratio (L/V ratio) at postcapillary venules as a marker of hyalinizing vasculopathy. Demography and other data for the patients, including dialysate-to-plasma (D/P) ratio of creatinine, were obtained at baseline and every 6 months by peritoneal equilibration test.
RESULTS: Between 2002 and 2009, 110 patients started PD therapy with biocompatible dialysate at Tokyo University Hospital. Among them, 11 patients (8 men, 3 women; age: 54.2 ± 11.8 years; 1 with diabetes mellitus) were enrolled into this morphology study. The mean duration of PD in this group was 61 ± 11.3 months, and the mean time to peritoneal biopsy was 58 ± 15.1 months. The median APT was 180 μm (96 - 1424 μm), and the median L/V ratio was 0.66 (0.46 - 0.74). No obvious correlations between APT, L/V ratio, and PD duration were detected. The D/P creatinine of the 11 patients was maintained at a favorably low value, comparable with that of the other 99 patients.
CONCLUSIONS: Peritoneal dialysis therapy using biocompatible dialysate in conjunction with modification of clinical practice may minimize the progression of peritoneal interstitial sclerosis and hyalinizing vasculopathy, preserving favorable peritoneal function for more than 3 years.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21804136      PMCID: PMC3525415          DOI: 10.3747/pdi.2010.00234

Source DB:  PubMed          Journal:  Perit Dial Int        ISSN: 0896-8608            Impact factor:   1.756


  39 in total

1.  Morphologic changes in the peritoneal membrane of patients with renal disease.

Authors:  John D Williams; Kathrine J Craig; Nicholas Topley; Christopher Von Ruhland; Maureen Fallon; Geoffrey R Newman; Ruth K Mackenzie; Geraint T Williams
Journal:  J Am Soc Nephrol       Date:  2002-02       Impact factor: 10.121

2.  Long-term results with low glucose degradation product content in peritoneal dialysis fluids.

Authors:  Bengt Rippe; Anders Wieslander; Barbara Musi
Journal:  Contrib Nephrol       Date:  2003       Impact factor: 1.580

3.  2009 Japanese Society for Dialysis Therapy guidelines for peritoneal dialysis.

Authors: 
Journal:  Ther Apher Dial       Date:  2010-12       Impact factor: 1.762

4.  Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis.

Authors:  Simon J Davies; Louise Phillips; Patrick F Naish; Gavin I Russell
Journal:  J Am Soc Nephrol       Date:  2001-05       Impact factor: 10.121

5.  Glucose degradation products in PD fluids: do they disappear from the peritoneal cavity and enter the systemic circulation?

Authors:  Martin Zeier; Vedat Schwenger; Reinhold Deppisch; Ulrike Haug; Kai Weigel; U Bahner; Christoph Wanner; H Schneider; Thomas Henle; Eberhard Ritz
Journal:  Kidney Int       Date:  2003-01       Impact factor: 10.612

6.  Influence of neutral-pH dialysis solutions on the peritoneal membrane: a long-term investigation in rats.

Authors:  K Wieczorowska-Tobis; A Polubinska; T P Schaub; H Schilling; J Wisniewska; J Witowski; J Passlick-Deetjen; A Breborowicz
Journal:  Perit Dial Int       Date:  2001       Impact factor: 1.756

7.  Structural and functional alterations of the peritoneum after prolonged exposure to dialysis solutions: role of aminoguanidine.

Authors:  E A Lee; J H Oh; H A Lee; S I Kim; E W Park; K B Park; M S Park
Journal:  Perit Dial Int       Date:  2001 May-Jun       Impact factor: 1.756

8.  Better preservation of peritoneal morphologic features and defense in rats after long-term exposure to a bicarbonate/lactate-buffered solution.

Authors:  Liesbeth H P Hekking; Mohammad Zareie; Bas A J Driesprong; Dirk Faict; Angelique G A Welten; Inge de Greeuw; Inge L Schadee-Eestermans; Carin E G Havenith; Jacob van den Born; Piet M Ter Wee; Robert H J Beelen
Journal:  J Am Soc Nephrol       Date:  2001-12       Impact factor: 10.121

9.  Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products.

Authors:  B Rippe; O Simonsen; O Heimbürger; A Christensson; B Haraldsson; G Stelin; L Weiss; F D Nielsen; S Bro; M Friedberg; A Wieslander
Journal:  Kidney Int       Date:  2001-01       Impact factor: 10.612

Review 10.  Formation of advanced glycation end products during CAPD.

Authors:  Andreas Tauer; Xiaohong Zhang; Thomas P Schaub; Thomas Zimmeck; Toshimitsu Niwa; Jutta Passlick-Deetjen; Monika Pischetsrieder
Journal:  Am J Kidney Dis       Date:  2003-03       Impact factor: 8.860

View more
  17 in total

1.  Normal peritoneum after nine years of peritoneal dialysis with biocompatible dialysate: a case report.

Authors:  Y Kamijo; H Iida; K Saito; R Furutera; Y Ishibashi
Journal:  Perit Dial Int       Date:  2013 Nov-Dec       Impact factor: 1.756

2.  Normal peritoneal histology after ten years of peritoneal dialysis in a contemporary Japanese patient.

Authors:  M Tsukamoto; Y Ishibashi; Y Takazawa; Y Komemushi; H Kume
Journal:  Perit Dial Int       Date:  2013 Jul-Aug       Impact factor: 1.756

3.  Morphological characteristics in peritoneum in patients with neutral peritoneal dialysis solution.

Authors:  Chieko Hamada; Kazuho Honda; Kunio Kawanishi; Hirotaka Nakamoto; Yasuhiko Ito; Tsutomu Sakurada; Yudo Tanno; Toru Mizumasa; Masanobu Miyazaki; Misaki Moriishi; Masaaki Nakayama
Journal:  J Artif Organs       Date:  2015-02-14       Impact factor: 1.731

4.  PD Solutions and Peritoneal Health.

Authors:  Yeoungjee Cho; David W Johnson
Journal:  Clin J Am Soc Nephrol       Date:  2018-08-31       Impact factor: 8.237

5.  Biocompatible Dialysis Solutions Preserve Peritoneal Mesothelial Cell and Vessel Wall Integrity. A Case-Control Study on Human Biopsies.

Authors:  Gloria del Peso; José Antonio Jiménez-Heffernan; Rafael Selgas; César Remón; Marta Ossorio; Antonio Fernández-Perpén; José Antonio Sánchez-Tomero; Antonio Cirugeda; Erika de Sousa; Pilar Sandoval; Raquel Díaz; Manuel López-Cabrera; María Auxiliadora Bajo
Journal:  Perit Dial Int       Date:  2015-10-16       Impact factor: 1.756

6.  Baseline serum interleukin-6 predicts cardiovascular events in incident peritoneal dialysis patients.

Authors:  Yeoungjee Cho; David W Johnson; David A Vesey; Carmel M Hawley; Elaine M Pascoe; Margaret Clarke; Nicholas Topley
Journal:  Perit Dial Int       Date:  2014-04-07       Impact factor: 1.756

7.  Higher Dialysate Matrix Metalloproteinase-2 Levels Are Associated with Peritoneal Membrane Dysfunction.

Authors:  Yeoungjee Cho; David W Johnson; David A Vesey; Carmel M Hawley; Elaine M Pascoe; Margaret Clarke; Nicholas Topley
Journal:  Perit Dial Int       Date:  2014-10-07       Impact factor: 1.756

8.  Encapsulating peritoneal sclerosis in the era of a multi-disciplinary approach based on biocompatible solutions: the NEXT-PD study.

Authors:  Masaaki Nakayama; Masanobu Miyazaki; Kazuho Honda; Kenji Kasai; Tadashi Tomo; Hidetomo Nakamoto; Hideki Kawanishi
Journal:  Perit Dial Int       Date:  2014-02-04       Impact factor: 1.756

9.  Low-GDP, pH-neutral solutions preserve peritoneal endothelial glycocalyx during long-term peritoneal dialysis.

Authors:  Naoya Sugiyama; Mitsuhiro Tawada; Ting Sun; Yasuhiro Suzuki; Hiroshi Kinashi; Makoto Yamaguchi; Takayuki Katsuno; Jan Aten; Carmen A Vlahu; Toin H van Kuppevelt; Yoshifumi Takei; Takuji Ishimoto; Shoichi Maruyama; Masashi Mizuno; Yasuhiko Ito
Journal:  Clin Exp Nephrol       Date:  2021-05-17       Impact factor: 2.801

10.  Transcriptional patterns in peritoneal tissue of encapsulating peritoneal sclerosis, a complication of chronic peritoneal dialysis.

Authors:  Fabian R Reimold; Niko Braun; Zsuzsanna K Zsengellér; Isaac E Stillman; S Ananth Karumanchi; Hakan R Toka; Joerg Latus; Peter Fritz; Dagmar Biegger; Stephan Segerer; M Dominik Alscher; Manoj K Bhasin; Seth L Alper
Journal:  PLoS One       Date:  2013-02-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.